Cassava Sciences, Inc.
SAVA
$2.05
-$0.07-3.30%
NASDAQ
03/31/2025 | 12/31/2024 | 09/30/2024 | 06/30/2024 | 03/31/2024 | |
---|---|---|---|---|---|
Revenue | -- | -- | -- | -- | -- |
Total Other Revenue | -- | -- | -- | -- | -- |
Total Revenue | -- | -- | -- | -- | -- |
Cost of Revenue | 13.67M | -42.62M | 17.68M | 972.00K | 16.23M |
Gross Profit | -13.67M | 42.62M | -17.68M | -972.00K | -16.23M |
SG&A Expenses | 7.92M | -943.00K | 14.05M | 46.20M | 6.70M |
Depreciation & Amortization | -- | -- | -- | -- | -- |
Other Operating Expenses | -- | -- | -- | -- | -- |
Total Operating Expenses | 21.59M | 19.59M | 31.72M | 61.40M | 22.93M |
Operating Income | -21.59M | -19.59M | -31.72M | -61.40M | -22.93M |
Income Before Tax | -23.40M | -27.60M | -27.94M | 6.16M | 25.04M |
Income Tax Expenses | -- | -- | -- | -- | -- |
Earnings from Continuing Operations | -23.40M | -27.60M | -27.94M | 6.16M | 25.04M |
Earnings from Discontinued Operations | -- | -- | -- | -- | -- |
Extraordinary Item & Accounting Change | -- | -- | -- | -- | -- |
Minority Interest in Earnings | -- | -- | -- | -- | -- |
Net Income | -23.40M | -27.60M | -27.94M | 6.16M | 25.04M |
EBIT | -21.59M | -19.59M | -31.72M | -61.40M | -22.93M |
EBITDA | -21.37M | -19.33M | -31.46M | -61.10M | -22.62M |
EPS Basic | -0.48 | -0.57 | -0.58 | 0.13 | 0.58 |
Normalized Basic EPS | -0.26 | -0.23 | -0.38 | 0.08 | 0.32 |
EPS Diluted | -0.48 | -0.57 | -0.58 | 0.13 | -0.43 |
Normalized Diluted EPS | -0.26 | -0.23 | -0.38 | 0.08 | 0.31 |
Average Basic Shares Outstanding | 48.26M | 48.10M | 47.98M | 46.20M | 43.00M |
Average Diluted Shares Outstanding | 48.26M | 48.10M | 47.98M | 46.20M | 44.10M |
Dividend Per Share | -- | -- | -- | -- | -- |
Payout Ratio | -- | -- | -- | -- | -- |